Cytek Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Cytek Biosciences

28/02/2023 23:03

* Cytek Biosciences Inc  CTKB.OQ  reported quarterly
adjusted
earnings of 6 cents​​ per share for the quarter ended in
December. The mean expectation of four analysts for the quarter
was for earnings of 5 cents per share.
    * Revenue rose 24.3% to $48.33 million from a year ago;
analysts
expected $50.22 million. 
    * Cytek Biosciences Inc's reported EPS for the quarter was 2
cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cytek Biosciences Inc shares had risen by 3.2% this
quarter.
    * The company reported quarterly net income of $3.53
million.
    * Wall Street's median 12-month price target for Cytek
Biosciences
Inc is $16.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 11:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      0.05           0.06           Beat
 Sep. 30 2022      0.02           0.04           Beat
 Jun. 30 2022      0.02           0.03           Beat
 Mar. 31 2022      0.00           0.01           Beat